Literature DB >> 16775594

A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders.

N Besbas1, D Karpman, D Landau, C Loirat, W Proesmans, G Remuzzi, G Rizzoni, C M Taylor, N Van de Kar, L B Zimmerhackl.   

Abstract

The diagnostic terms hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are based on historical and overlapping clinical descriptions. Advances in understanding some of the causes of the syndrome now permit many patients to be classified according to etiology. The increased precision of a diagnosis based on causation is important for considering logical approaches to treatment and prognosis. It is also essential for research. We propose a classification that accommodates both a current understanding of causation (level 1) and clinical association in cases for whom cause of disease is unclear (level 2). We tested the classification in a pediatric disease registry of HUS. The revised classification is a stimulus to comprehensive investigation of all cases of HUS and TTP and is expected to increase the proportion of cases in whom a level 1 etiological diagnosis is confirmed.

Entities:  

Mesh:

Year:  2006        PMID: 16775594     DOI: 10.1038/sj.ki.5001581

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  85 in total

1.  Thrombotic microangiopathy: atypical HUS: current diagnostic and therapeutic approaches.

Authors:  Alejandra Rosales; Magdalena Riedl; Lothar B Zimmerhackl
Journal:  Nat Rev Nephrol       Date:  2010-09       Impact factor: 28.314

2.  Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Authors:  Olga Nikolajeva; Austen Worth; Rosie Hague; Nuria Martinez-Alier; Joanne Smart; Stuart Adams; E Graham Davies; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

Review 3.  Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.

Authors:  Caitlin E Carter; Nadine M Benador
Journal:  Pediatr Nephrol       Date:  2013-06-29       Impact factor: 3.714

Review 4.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

5.  An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome.

Authors:  Sally Johnson; Jelena Stojanovic; Gema Ariceta; Martin Bitzan; Nesrin Besbas; Michelle Frieling; Diana Karpman; Daniel Landau; Craig Langman; Christoph Licht; Carmine Pecoraro; Magdalena Riedl; Ekaterini Siomou; Nicole van de Kar; Johan Vande Walle; Chantal Loirat; C Mark Taylor
Journal:  Pediatr Nephrol       Date:  2014-05-11       Impact factor: 3.714

Review 6.  Therapeutic targets in focal and segmental glomerulosclerosis.

Authors:  Peter J Lavin; Rasheed Gbadegesin; Tirupapuliyur V Damodaran; Michelle P Winn
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-07       Impact factor: 2.894

7.  Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.

Authors:  Johannes Hofer; Andreas R Janecke; L B Zimmerhackl; Magdalena Riedl; Alejandra Rosales; Thomas Giner; Gerard Cortina; Carola J Haindl; Barbara Petzelberger; Miriam Pawlik; Verena Jeller; Udo Vester; Bettina Gadner; Michael van Husen; Michael L Moritz; Reinhard Würzner; Therese Jungraithmayr
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

8.  Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation.

Authors:  F Semsa Cayci; Nilgun Cakar; Veysel Sabri Hancer; Nermin Uncu; Banu Acar; Gokce Gur
Journal:  Pediatr Nephrol       Date:  2012-08-19       Impact factor: 3.714

Review 9.  Advances and challenges in the management of complement-mediated thrombotic microangiopathies.

Authors:  Jean-Claude Davin; Nicole C A J van de Kar
Journal:  Ther Adv Hematol       Date:  2015-08

Review 10.  Renal complications of seasonal and pandemic influenza A virus infections.

Authors:  Toru Watanabe
Journal:  Eur J Pediatr       Date:  2012-10-13       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.